Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02669433 · ClinicalTrials.gov registry record · Phase 2
Study Evaluating Intepirdine (RVT-101) in Subjects With Dementia With Lewy Bodies: The HEADWAY-DLB Study
A Phase 2 study, sponsored by Axovant Sciences.
- Completed
- Registry status
- Phase 2
- Development phase
- 484
- Enrollment target
NCT02669433 is a Phase 2 study that has completed, run by Axovant Sciences. The registered enrollment target is 484 participants.
The verdict
NCT02669433, a Phase 2 study, has completed, sponsored by Axovant Sciences.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 484 participants
- Enrollment target
Study Summary
This study seeks to evaluate the efficacy and safety of intepirdine (RVT-101) in patients with dementia with Lewy bodies.
Interventions
- DRUG Placebo
- DRUG RVT-101 35 mg
- DRUG RVT-101 70 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 484 participants |
| Start Date | 2016-01 |
| Est. Completion | 2017-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02669433
The ClinicalTrials.gov registry entry for NCT02669433 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 484 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Axovant Sciences, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT02669433 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02669433 about?
NCT02669433 is a clinical study titled "Study Evaluating Intepirdine (RVT-101) in Subjects With Dementia With Lewy Bodies: The HEADWAY-DLB Study". This study seeks to evaluate the efficacy and safety of intepirdine (RVT-101) in patients with dementia with Lewy bodies.
What is the current status of trial NCT02669433?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 484 participants. The study started on 2016-01. Estimated completion is 2017-12.
What interventions are being tested in trial NCT02669433?
The interventions under investigation include: Placebo (DRUG), RVT-101 35 mg (DRUG), RVT-101 70 mg (DRUG).
Who is sponsoring clinical trial NCT02669433?
This trial is sponsored by Axovant Sciences, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.